Clinical Trials Logo

Renal Cell Cancer Metastatic clinical trials

View clinical trials related to Renal Cell Cancer Metastatic.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06264479 Not yet recruiting - Kidney Cancer Clinical Trials

Prospective Evaluation of AI R&D Tool for Patient Stratification: a Trial for Renal Immuno-oncology Model Experimental Evaluation 2

PEAR-TREE2
Start date: May 1, 2024
Phase:
Study type: Observational

Pear Bio has developed a predictive biomarker technology that combines 3D cell culture, microscopy and computer vision to measure the response of an individual patient's tumor sample to different systemic therapy regimens that are tested simultaneously ex vivo. This study will recruit patients with advanced or metastatic kidney cancer who are due to start a clinically-indicated new line of therapy. The oncologist will be blinded to the response on the Pear Bio test (the test will be run in parallel with the patient's treatment). The primary objective of this study is to establish the sensitivity and specificity of Pear Bio's test results against patient outcomes (objective response, progression-free survival, depth and duration of response, overall survival).